Learn More
1576 Background: Despite considerable progress in the treatment modalities used for brain tumors (surgery, radiation therapy and chemotherapy), local recurrence continues to be an important reason(More)
The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents.(More)